Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov 16;9(11):e00905.
doi: 10.14309/crj.0000000000000905. eCollection 2022 Nov.

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity

Davide De Marco  1 , Talat Bessissow  1 , Victoria Marcus  2 , Amine Benmassaoud  1
Affiliations
Case Reports

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity

Davide De Marco et al. ACG Case Rep J. .

Abstract

Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiation. A complete workup for causes of hepatitis and hypereosinophilia was negative, and liver biopsy showed signs compatible with drug-induced liver injury. After the withdrawal of vedolizumab, the patient's eosinophil count and liver enzymes normalized. As vedolizumab becomes more prominent, it is important to understand the potential side-effect profile of vedolizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Periductal fibrosis on liver biopsy (Masson trichrome stain, ×400).
Figure 2.
Figure 2.
Moderate eosinophilic infiltrate seen on liver biopsy (hematoxylin and eosin [H&E] stain, ×400).
See this image and copyright information in PMC

References

    1. Loftus EV, Jr, Feagan BG, Panaccione R, et al. . Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353–65. - PMC - PubMed
    1. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2012. - PubMed
    1. Vedolizumab (Entyvio) [package insert]. Takeda Pharamceuticals America: Deerfield, IL, 2014.
    1. Honap S, Sticova E, Theocharidou E, et al. . Vedolizumab-associated drug-induced liver injury: A case series. Inflamm Bowel Dis. 2021;27(3):e32–e34. - PubMed
    1. Saraiva MM, Ribeiro T, Dias E, Lopes JL, Cardoso H, Macedo G. Vedolizumab-induced liver injury. GE-Portuguese J Gastroenterol. 2021;28(6):410–5. - PMC - PubMed

Publication types